Myocardial Titin and Collagen in Cardiac Diastolic Dysfunction
Partners in Crime

Nazha Hamdani, PhD; Walter J. Paulus, MD, PhD

High myocardial diastolic stiffness has usually been attributed to excessive myocardial collagen deposition. Over the last decade, stiff cardiomyocytes were also identified as important contributors to high myocardial diastolic stiffness, especially in heart failure (HF) with preserved ejection fraction (HFPEF).1–3 Cardiomyocyte stiffness relates to elasticity of the giant cytoskeletal protein titin, which spans the sarcomere from the Z disk to the M line and functions as a bidirectional spring responsible for early diastolic recoil and late diastolic distensibility of cardiomyocytes.4 In HFPEF patients and in HFPEF animal models,5 the observed increase in cardiomyocyte stiffness was always accompanied by increased deposition of collagen; therefore, it remained unclear whether impaired elasticity of titin could be solely responsible for high myocardial diastolic stiffness and HFPEF. In this issue of Circulation, however, Chung et al6 provide compelling evidence for titin being the sole perpetrator in the diastolic myocardial titin to be able to sufficiently compromise diastolic LV function to induce HFPEF.

The Adjustable Spring Properties of Titin

Titin, with a molecular mass of up to 3800 kDa, spans half-sarcomeres from the Z disk to the M band and contains a molecular spring segment, the I-band region, that supports early diastolic recoil and late diastolic resistance to stretch (Figure 1A). The I-band region has a complex structure comprising 3 extensible segments: tandem Ig-like domain regions with a proximal and a distal segment, a proline-glutamate-valine-lysine segment, and a unique sequence that is part of the N2B element (N2-Bus) and expressed only in cardiac titin. In the study by Chung et al,6 9 Ig-like domains from the proximal tandem Ig segment were deleted. This shortened the overall length of titin and increased titin stiffness. Changes in titin stiffness have also been reported after isoform shifts or posttranslational modifications like phosphorylation or oxidation. The 2 main titin isoforms expressed in human (and other mammalian) hearts are N2B, which is the shorter and stiffer isoform, and N2BA, which is the longer and more compliant isoform.6 Higher expression of the N2BA titin isoform was reported in eccentrically remodeled hearts of ischemic or dilated cardiomyopathy.4 In contrast, only a minor shift toward the N2BA titin isoform was observed in concentrically remodeled hearts of HFPEF patients (Figure 1B).7 Titin also adjusts cardiomyocyte stiffness through posttranslational modifications like phosphorylation or oxidation (Figure 1C and 1D). Protein kinase A8 and protein kinase G9 phosphorylate titin at its N2B segment. This allows β-adrenergic stimulation, nitric oxide, or natriuretic peptides to acutely lower cardiomyocyte stiffness. In HFPEF, titin is hypophosphorylated,7 probably as a result of low myocardial protein kinase G activity induced by low nitric oxide bioavailability and high oxidative stress.5 Protein kinase Cα phosphorylates titin at its proline-glutamate-valine-lysine region. Protein kinase Cα administration raises the stiffness of cardiomyocytes isolated from normal myocardium10 but has no effect on cardiomyocytes retrieved from an animal model.11 Titin can also be phosphorylated by extracellular signal-regulated kinase-212 and at several sites by calcium calmodulin-dependent kinase II.13 Both extracellular signal-regulated kinase-2 and calcium calmodulin-dependent kinase II lower cardiomyocyte stiffness. The pathophysiological relevance of phosphorylation by protein kinase Cα, extracellular signal-regulated kinase-2, and calcium calmodulin-dependent kinase II for diastolic LV dysfunction in HFPEF remains to be elucidated. Finally, the stiffness of cardiomyocytes also rises in the presence of oxidative stress because of formation within the titin molecule of disulfide bridges, which reduce the contour length of the N2B segment (Figure 1D).14

Interstitial Collagen: A Loose or a Tight Fit?

In diastolic LV dysfunction, cardiomyocyte stiffness and collagen deposition are often unequally involved. Resting tension of isolated cardiomyocytes stretched to 2.2-µm sarcomere length (Fpassive) and myocardial collagen volume fraction...
(CVF) were simultaneously assessed in several HF animal models and in patients with HFPEF, HF with reduced ejection fraction, and aortic stenosis. Titin IG KO mice and obese ZSF1 rats are at one end of the spectrum with a 2.0-times increase in Fp and no change in CVF. Patients with aortic stenosis are at the other end of the spectrum with no change in Fp and a 2.4-times increase in CVF. HFPEF patients occupy an intermediate position with a 2.0-times increase in Fp and a 2.3-times increase in CVF, whereas patients with HF with reduced ejection fraction come close to aortic stenosis patients, presenting with a 1.5-times increase in Fp and a 2.6-times increase in CVF.

Apart from unequal involvement in different HF phenotypes, cardiomyocyte stiffness and collagen deposition can also vary widely within a single HF phenotype. When HFPEF patients were classified according to myocardial CVF (low, <5%; intermediate, 5%–10%; high, >10%), they were equally distributed over the 3 classes of CVF. Furthermore, LV end-diastolic pressure, circumferential LV end-diastolic wall stress, and radial myocardial stiffness modulus were similarly

Figure 1. Adjustable spring properties of titin. A, Structural components and phosphorylation sites of N2BA titin. The orange box shows the Ig domain deleted in the study of Chung et al. B through D, Modulation of cardiomyocyte stiffness (passive-length tension relation) by titin isoform shift (B), by titin phosphorylation (C), and by oxidation (D). CaMKII indicates calcium calmodulin dependent kinase II; ERK2, extracellular signal-regulated kinase-2; N2-Bus, unique sequence; P, phosphorylation site; PKA, protein kinase A; PKCα, protein kinase Cα; PKG, protein kinase G; and S, sulfide.

Figure 2. Titin- and matrix-based components of the myocardial passive-length tension relation. Myocardial passive-length tension relation and its components in normal myocardium (A), in the presence of a stiffer titin (B), and in the presence of a stiffer matrix (C). Fp indicates the resting tension of isolated cardiomyocytes.
The very low cGMP content does not seem to be substantially lowered stiffness of titin. Increasing myocardial protein deposition cannot be inferred from simple measurements of CVF and cardiomyocyte Fνbasin at 2.2-μm sarcomere length but requires an integrated assessment of elasticity of cardiomyocytes and of extracellular matrix over the entire physiological distension range of cardiac muscle. The study by Chung et al in this issue of Circulation and 2 other recent studies nicely illustrate how this can be achieved. In these studies, passive length-tension relations of skin-anchored cardiac muscle strips were obtained before and after KI/KCl administration, which extracts thick and thin filaments and leaves titin unanchored. The passive length-tension relation after KI/KCl therefore corresponds to the elasticity of the extracellular matrix. By subtracting this relation from the relation before KI/KCl administration, the elasticity attributable to titin can be calculated. In normal myocardium (Figure 2A), titin accounts for cardiac muscle elasticity at low and intermediate sarcomere lengths. Collagen starts to contribute at high sarcomere lengths, and at the outer limit of the physiological range of sarcomere lengths (2.3 μm), the contributions of collagen and titin equalize. When titin is stiffer than normal (Figure 2B), equalization occurs beyond the outer limit, and the fit of interstitial collagen around cardiomyocytes becomes “loose” over the physiological range of sarcomere lengths. When there is excessive collagen deposition (Figure 2C), equalization occurs at intermediate sarcomere length, and the fit of interstitial collagen becomes “tight.” When both titin and extracellular matrix are stiffer, equalization again occurs at the outer limit of physiological sarcomere lengths, and the relative importance of titin and collagen resembles the normal situation. This last situation was nicely illustrated in mice that developed HF after transverse aortic constriction. These mice had a 2-fold increase in cardiomyocyte-based stiffness, a 3-fold rise in extracellular matrix–based stiffness, and equalization of the contributions of titin and collagen at the outer limit of the physiological range of sarcomere lengths. The foregoing shows interstitial collagen deposition, which varies widely between and within HF phenotypes, to exert its restraining effect on LV filling in a titin-dependent fashion.

Therapeutic Implications

A stiffer titin has previously been observed to increase cardiomyocyte stiffness in HFPEF. The study of Chung et al provides proof of principle that stiffer titin suffices to induce HFPEF without any involvement of the extracellular matrix. This observation turns titin into a prime therapeutic target in HFPEF. Phosphorylation by protein kinase A or G effectively lowers stiffness of titin. Increasing myocardial protein kinase A activity by β-adrenergic stimulation, however, is obsolete because of the risk of arrhythmic death. Raising myocardial protein kinase G activity is a valid alternative because myocardial protein kinase G activity and cGMP content are 2 and 8 times lower, respectively, in HFPEF myocardium. The very low cGMP content does not seem to be substantially improved by blocking cGMP breakdown, as evident from the Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (RELAX) trial, in which sildenafil failed to significantly raise plasma cGMP levels or to ameliorate diastolic LV dysfunction. Restoring myocardial cGMP content probably requires the supply of cGMP to be boosted either by increasing myocardial nitric oxide bioavailability or by increasing natriuretic peptide signaling. The former can be achieved by stringent control of metabolic comorbidities; the latter, by the novel angiotensin receptor nephrisin inhibitor LCZ696, which inhibits the breakdown of natriuretic peptides and was recently shown in a phase II study to improve diastolic LV dysfunction of HFPEF patients. Finally, as insight into post-translational modifications of titin progresses, other new therapeutic in-roads will appear that reduce stiffness of titin and improve diastolic LV dysfunction in HFPEF.

Source of Funding
Drs Hamdani and Paulus are supported by a grant from the European Commission (FP7-Health-2010; MEDIA-261409).

Disclosures
None.

References
11. Hamdani N, Bishu KG, von Frieling-Salewsky M, Redfield MM, Linke WA. Deranged myofilament phosphorylation and function in...


**Key Words:** Editorials ■ collagen ■ diastole ■ heart failure ■ titin ■ ventricular function left
Myocardial Titin and Collagen in Cardiac Diastolic Dysfunction: Partners in Crime
Nazha Hamdani and Walter J. Paulus

Circulation. 2013;128:5-8: originally published online May 24, 2013;
doi: 10.1161/CIRCULATIONAHA.113.003437
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the
World Wide Web at:
http://circ.ahajournals.org/content/128/1/5

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published
in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial
Office. Once the online version of the published article for which permission is being requested is located,
click Request Permissions in the middle column of the Web page under Services. Further information about
this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/